A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder

References

• Jafari P, Ghanizadeh A, Akhondzadeh S, Mohammadi MR. Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Qual Life Res 2011;20:31–6.
   PubMed Web of Science ®Google Scholar
• Fazel S, Doll H, Langstrom N. Mental disorders among adolescents in juvenile detention and correctional facilities: A systematic review and metaregression analysis of 25 surveys. J Am Acad Child Adolesc Psychiatry 2008;47:1010–9.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Mohammadi MR, Akhondzadeh S, Sanaei-Zadeh H. Attention deficit hyperactivity disorder in imprisoned individuals—A review. Psychiatr Danub 2011;23: 139–44.
   PubMed Web of Science ®Google Scholar
• Einarsson E, Sigurdsson JF, Gudjonsson GH, Newton AK, Bragason OO. Screening for attention-deficit hyperactivity disorder and co-morbid mental disorders among prison inmates. Nord J Psychiatry 2009;63:361–7.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Jarvelin MR, Obel C, Taanila A, Miettunen J, Moilanen I, et al. Do inattention and hyperactivity symptoms equal scholastic impairment? Evidence from three European cohorts. BMC Public Health 2007;7:327.
   PubMed Web of Science ®Google Scholar
• Kadesjö B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school‐age children. J Child Psychol Psychiatry 2001;42:487–92.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Mohammadi MR, Moini R. Comorbidity of psychiatric disorders and parental psychiatric disorders in a sample of Iranian children with ADHD. J Atten Disord 2008;12:149–55.
   PubMed Web of Science ®Google Scholar
• Zuvekas SH, Vitiello B. Stimulant medication use in children: A 12-year perspective. Am J Psychiatry 2012;169:160–6.
   PubMed Web of Science ®Google Scholar
• Zoega H, Furu K, Halldorsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiat Scand 2011;123:360–7.
   PubMed Web of Science ®Google Scholar
• Nylander L, Holmqvist M, Gustafson L, Gillberg C. Attention- deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in adult psychiatry. A 20-year register study. Nord J Psychiatry 2013;67:344–50.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21–31.
   PubMed Web of Science ®Google Scholar
• Sepulveda DR, Thomas LM, McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: Preliminary analysis among college students. J Pharm Pract 2011;24:551–60.
   PubMedGoogle Scholar
• Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408–14.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007;68 Suppl 11:15–22.
   PubMed Web of Science ®Google Scholar
• King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006;10:iii–iv, xiii–146.
   PubMed Web of Science ®Google Scholar
• Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011;27 Suppl 2:13–22.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A. Co-morbidity and factor analysis on attention deficit hyperactivity disorder and autism spectrum disorder DSM-IV-derived items. J Res Med Sci 2012;17.
   Web of Science ®Google Scholar
• Ghanizadeh A. Atomoxetine for treating ADHD symptoms in autism: A systematic review. J Atten Disord 2013;17: 635–40.
   PubMed Web of Science ®Google Scholar
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and clinical profile. CNS Drug Rev 2004;10:23–44.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009;6:e1000100.
   PubMed Web of Science ®Google Scholar
• Elia N, Tramer MR. Ketamine and postoperative pain—A quantitative systematic review of randomised trials. Pain 2005;113:61–70.
   PubMed Web of Science ®Google Scholar
• Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; A systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735–44.
   PubMed Web of Science ®Google Scholar
• Arabgol F, Hebrani P, Ashtiani RD, Panaghi L, shams J. Reboxetine versus methylphenidate in the treatment of children and adolescents with attention deficit hyperactivity disorder. Pejouhandeh 2007;12:79–86.
   Google Scholar
• Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 2009;18:53–9.
   PubMed Web of Science ®Google Scholar
• Riahi F, Tehrani-Doost M, Shahrivar Z, Alaghband-Rad J. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial. Hum Psychopharmacol 2010;25:570–6.
   PubMed Web of Science ®Google Scholar
• Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: An open-label, 8-week, methylphenidate- controlled trial. Clin Neuropharmacol 2009;32:179–82.
   PubMed Web of Science ®Google Scholar
• Cak HT, Cetin FC. Reboxetine use in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:803–4.
   PubMed Web of Science ®Google Scholar
• Otka JE, Mercadante MT, Scahill L, Leckman JF. Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:203–4.
   PubMed Web of Science ®Google Scholar
• Quintero J, Lopez-Munoz F, Alamo C, Loro M, Garcia-Campos N. Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: A prospective long-term open-label study. Atten Defic Hyperact Disord 2010;2:107–13.
   PubMedGoogle Scholar
• Tehrani-Doost M, Moallemi S, Shahrivar Z. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;18:179–84.
   PubMed Web of Science ®Google Scholar
• Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A. A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: Case series. Neuropsychobiology 2005;51:239–42.
   PubMed Web of Science ®Google Scholar
• Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A. Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial. J Child Adolesc Psychopharmacol 2005;15:259–69.
   PubMed Web of Science ®Google Scholar
• Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G, Laor N. Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: A long-term follow-up study. J Child Adolesc Psychopharmacol 2007;17:803–12.
   PubMed Web of Science ®Google Scholar
• Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005;44:428–33.
   PubMed Web of Science ®Google Scholar
• Arabgol F, Panaghi L, Hakim-Shooshtari M, Hebrani P. Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder. Tehran Univ Med J (TUMJ) 2007;65.
   Google Scholar
• Hashemian F, Mohammadian S, Riahi F, Ghaeli P, Ghodsi D. A comparison of the effects of reboxetine and placebo on reaction time in adults with attention deficit-hyperactivity disorder (ADHD). DARU J Pharmaceut Sci 2011;19:231–5.
   Google Scholar